Estrone Saliva ELISA
- Regulatory Status
- EU: CE
- Kit size
- 12 x 8
- Method
- ELISA
- Incubation time
- 2 x 30 min, 1 x 15 min
- Standard range
- 3 - 333 pg/mL
- Specimen / Volumes
- 100 µL Saliva
- Substrate / isotope
- TMB 450 nm
Intended Use
Enzyme Immunoassay for the quantitative measurement of Estrone in saliva.
Summary and Explanation
Estrone (3-hydroxy-1,3,5 (10)-estratrien–17-one) is beside estradiol and estriol one of the three major naturally occurring estrogens. The estrogens are involved in the development of female sex organs and secondary sex characteristics. Bioassay data indicate that the estrogenic activity of estrone is considerably lower in comparison to estradiol. However, the physiological role of endogenous estrone is not well defined. Estrone is produced primarily from androstenedione. In premenopausal women, more than 50% of the estrone is secreted by the ovary. In prepubertal children, men and postmenopausal women, the major portion of estrone is derived from peripheral tissue conversion. During the follicular phase of the menstrual cycle the estrone level inreases with a clear peak around day 13. The peak is of short duration and by day 16 of the cycle levels will be low again. A second peak during the luteal phase occurs around day 21 of the cycle. If fertilization does not occur production of estrone decreases again. These changes of estrone concentration are in parallel to that of estradiol. Until the 4th to 6th week of pregnancy, estrone originates primarily from maternal sources such as the ovaries, adrenals, or peripheral conversion thus remaining within the normal values. After the 6th to 10th week of pregnancy the values increase gradually due to placental secretion of estrone. After menopause, estrone levels do not decline as dramatically as estradiol levels. In postmenopausal women estrone is the major estrogen. In males the concentration of E1 has been reported to rise up with age inversely to that of 17-OH-progesterone. In premenopausal women excessive estrone levels can result from the conversion of large amounts of androstenedione produced in polycystic ovary syndrom and ovarian tumors.
For concrete data please consult the Instruction for Use in the download box on the top right side.
- Resnik R, Killam AP, Battaglia FC et al: The stimulation of uterine blood flow by various estrogens. Endocrinology 94:1192, 1974.
- Fayman C, Winter JSD, Reyes FI. Patterns of gonadotropins and gonadal steroids throughout life. Clin. Obstet. Gynecol. 3: 467-483, 1976.
- Baird DT. Fraser IS. Blood production and ovarian secretion rates of estradiol-17ß and estrone in women throughout the menstrual cycle. J Clin Endocrinol. Metab 38: 1009-1017. 1974
- Lindbert BS, Johansson EDB, Nilsson BA: Plasma levels of non conjugated oestrone, oestradiol-17b and oestriol during uncomplicated pregnancy. Acta Obstet Gynecol Scand 32:21, 1974.
- Drafta D, Schindler AE, Stroe EW, Neacsu E. Age-related changes of plasma steroids in normal adult males. J. Steroid Biochem. 17: 683-687, 1982.
- DeVane GW, Czekala NM, Judd HL, Yen SSC. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol 1975; 121:496.
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.